Gender Implications on Left Ventricular Diastolic Dysfunction in Non Alcoholic Fatty Liver Disease Patients
Main Article Content
Abstract
Objective: To assess the impact of gender on the risk of Left Ventricular Diastolic Dysfunction in Non Alcoholic Fatty Liver Disease.
Methodology: This comparative cross sectional study was conducted at the major hospitals of Khyber Pakhtunkhwa, after proper ethical approval was taken. The sample size was 192, using the non probability purposive sampling. All patients having non alcoholic fatty liver disease on imaging studies were screened for Left Ventricular Diastolic Dysfunction (LVDD) and then were included in the study. Patient with deranged liver function tests and having liver cirrhosis were excluded. The data analysis was conducted using SPSS 23 software package.
Results: The mean BMI of the patients was 20. The males comprised 53%(n-102) of the total patients while females accounted for 47% (n-90). The p value of 0.043 does show statistically significant difference in ventricular diastolic dysfunction between both the genders, especially more in female gender.
Conclusion: Left ventricular diastolic dysfunction is a common finding in Non Alcoholic Fatty Liver Disease patients having low BMI and female gender. Routine echocardiography should be performed to start the management on time.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Minich A, Arisar FAQ, Shaikh N ul S, Herman L, Azhie A, Orchanian-Cheff A, et al. Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis. eClinical Medicine 2022;50. DOI: 10.1016/j.eclinm.2022.101534.
2. Spiers J, Brindley JH, Li W, Alazawi W. What’s new in non-alcoholic fatty liver disease? Frontline Gastroenterol 2022;13(e1):E102-8.
3. Devi J, Raees A, Butt AS. Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible? World J Hepatol 2022;14(1):158-67.
4. Salah HM, Pandey A, Soloveva A, Abdelmalek MF, Diehl AM, Moylan CA, et al. Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction. JACC Basic to Transl Sci 2021;6(11):918-32.
5. Lee H, Lee Y-ho, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study. Clin Gastroenterol Hepatol 2021;19(10):2138-47.e10. DOI: 10.1016/j.cgh.2020.12.022.
6. Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): An update. Nutrients 2020;12(11):1-14.
7. Cai H, Qin YL, Shi ZY, Chen JH, Zeng MJ, Zhou W, et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: A randomised controlled trial. BMC Gastroenterol 2019;19(1):1-8.
8. Jafarikhah R, Damirchi A, Rahmani Nia F, Razavi-Toosi SMT, Shafaghi A, Asadian M. Effect of functional resistance training on the structure and function of the heart and liver in patients with non-alcoholic fatty liver. Sci Rep 2023;13(1):1-17. DOI: 10.1038/s41598-023-42687-w.
9. Gohil NV, Tanveer N, Makkena VK, Jaramillo AP, Awosusi BL, Ayyub J, et al. Non-alcoholic fatty liver disease and its association with left ventricular diastolic dysfunction: A systematic review. Cureus 2023;15(8):e43013.
10. Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42(6):e168-85.
11. Miptah HN, Ramli AS, Mohamad M, Hashim H, Tharek Z. Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: Is there an association? BMC Fam Pract 2020;21(1):1-12.
12. Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: A clinical review. Clin Res Cardiol 2021;110(7):921-37. DOI: 10.1007/s00392-020-01709-7.
13. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67(4):829-46.
14. Alaqaili HI, Aljuraysan AI, Hawsawi RMA. Review on liver cirrhosis complications and treatment. Egypt J Hosp Med 2017;69(8):3092-103.
15. Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021;27(16):1691-715.
16. Musazadeh V, Roshanravan N, Dehghan P, Ahrabi SS. Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver disease: An umbrella of systematic review and meta-analysis. Front Nutr 2022;9:1-10.
17. Sudhamshu KC, Prasad VGM, Shreshta A, Pathak R, Lama T, Jaisi B, et al. Nepal perspectives on routine clinical practices for management of NAFLD. J Liver 2020;9(1):240. DOI: 10.35248/2167-0889.20.9.240.